RBR-4jh63b尚未招募1 期
Mesenchymal stem cells for patients with Acute Respiratory Distress Syndrome and mechanical ventilation caused by COVID-19: a phase I/II study
StemCorp0 个研究点开始时间: 2020年11月19日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Intervention
入排标准
- 年龄范围
- 0 至 0（—）
入选标准
- •Patients aged 18 years or older; Admission to the ICU by COVID-19, confirmed by positive RT-PCR for SARS-CoV-2 (test registered by ANVISA); Diagnosis of acute respiratory distress syndrome related to COVID-19 and defined by changes in radiological images, gas exchange and the need for invasive mechanical ventilation (WHO classification 7 or higher); Be on invasive mechanical ventilation for a period greater than or equal to seven days; Absence of weaning from mechanical ventilation in the next 24 hours.
排除标准
- •Patients who are part of experimental treatments or who have participated in any clinical trial in the last 3 months; Patients who have some type of active cancer, according to the medical record of the ICU, which is generally based on clinical history obtained with the patient's family members; Patients with an autoimmune disease, according to the medical record of the ICU, which is generally based on clinical history obtained with the patient's family members; Pregnant and lactating patients. For female patients in reproductive age, a hCG test will be collected to exclude the possibility of pregnancy.
研究者
相似试验
招募中
2 期
Mesenchymal Stem Cell Therapy for Acute Respiratory Distress Syndrome in Coronavirus InfectioAcute Respiratory Distress Syndrome of COVID-19.COVID-19U07.1IRCT20200217046526N2Iranian academic center for education culture and research60
已完成
1 期
Mesenchymal Stem Cell Therapy for Acute Respiratory Distress Syndrome in Coronavirus InfectioIRCT20200217046526N1Iranian academic center for education culture and research6
进行中（未招募）
不适用
Mesenchymal stem cell based therapy for the treatment of osteogenesis imperfectaOsteogenesis imperfecta (OI) is a rare genetic disorder with increased bone fragility of varying severity. In the majority of patients the disease is caused by mutations in collagen type I. Severe OI is characterized by osteopenia, frequent fractures, progressive deformity, short stature, loss of mobility, chronic pain and can lead to premature death. At present a cure does not exist.EUCTR2012-002553-38-ESItziar Astigarraga Aguirre
进行中（未招募）
不适用
Therapeutic effect of mesenchymal cells in patients suffering from a disease characterized by a severe inflammation and/or in whom the immune system attacks their own tissues.MedDRA version: 14.0Level: LLTClassification code 10011402Term: Crohn's disease (colon)System Organ Class: 10017947 - Gastrointestinal disordersMedDRA version: 14.0Level: HLGTClassification code 10003816Term: Autoimmune disordersSystem Organ Class: 10021428 - Immune system disordersMedDRA version: 14.0Level: PTClassification code 10064147Term: Gastrointestinal inflammationSystem Organ Class: 10017947 - Gastrointestinal disordersMedDRA version: 14.0Level: PTClassification code 10011401Term: Crohn's diseaseSystem Organ Class: 10017947 - Gastrointestinal disordersCrohn's diseaseEUCTR2011-005966-39-BECHU-ULg20
招募中
1 期
Cell therapy with use of mesenchymal stem cells in infertile women with Thin EndometriumIRCT20230222057500N1Tehran University of Medical Sciences10